Uracil-tegafur in gastric carcinoma: a comprehensive review.

摘要: PURPOSEThe second-generation oral anticancer agent UFT, a combination of uracil and tegafur (TGF), results in higher fluorouracil (5-FU) concentration the tumor tissues than is achieved by TGF or comparable doses intravenous 5-fluorouracil. UFT has been extensively studied Japan use Orient for many years, particularly patients with gastric carcinoma. recently entered extensive investigations North America Europe.METHODSRelevant studies that have chronicled establishment its mechanism action, preclinical toxicology, human pharmacokinetics, phase I studies, activity against carcinoma are described detail.RESULTSThe slows degradation 5-FU dihydropyrimidine dehydrogenase (DPD), which sustained concentrations blood tissues. well tolerated, but such toxic effects as nausea, vomiting, diarrhea dose- schedule-dependent. In pharmacokinetic gi...